Dr. Amanda Cashen, MD
Claim this profileWashington University School of Medicine
About Amanda Cashen, MD
Education:
- MD from Washington University School of Medicine, 2015.
Experience:
- Completed Residency in Internal Medicine at Barnes-Jewish Hospital/Washington University School of Medicine, 2018.
- Finished Fellowship in Hematology and Oncology at Washington University School of Medicine, 2021.
- Serving as an Assistant Professor of Medicine at Washington University School of Medicine since 2023.
Area of expertise
Acute Myeloid Leukemia
Amanda Cashen, MD has run 8 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Non-Hodgkin's Lymphoma
Amanda Cashen, MD has run 5 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Siteman Cancer Center At West County Hospital
Clinical Trials Amanda Cashen, MD is currently running
Thiotepa + Stem Cell Transplant
for Lymphoma
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Recruiting
1 award
Phase 2
3 criteria
Memory-like NK Cells after Haploidentical Transplant
for AML
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Recruiting
1 award
Phase 1 & 2
12 criteria
More about Amanda Cashen, MD
Clinical Trial Related
9 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Amanda Cashen, MD has experience with
- Cytokine Induced Memory-like NK Cell Adoptive Therapy
- Nivolumab
- Rituximab
- Fludarabine
- Mosunetuzumab
- Autologous Hematopoietic Stem Cell Transplantation
Breakdown of trials Amanda Cashen, MD has run
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Graft-versus-Host Disease
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amanda Cashen, MD specialize in?
Amanda Cashen, MD focuses on Acute Myeloid Leukemia and Non-Hodgkin's Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved Stage IV patients, or patients who are undergoing treatment.
Is Amanda Cashen, MD currently recruiting for clinical trials?
Yes, Amanda Cashen, MD is currently recruiting for 4 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Amanda Cashen, MD has studied deeply?
Yes, Amanda Cashen, MD has studied treatments such as Cytokine Induced Memory-like NK Cell Adoptive Therapy, Nivolumab, Rituximab.
What is the best way to schedule an appointment with Amanda Cashen, MD?
Apply for one of the trials that Amanda Cashen, MD is conducting.
What is the office address of Amanda Cashen, MD?
The office of Amanda Cashen, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.